Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Cancer Immunotherapy and Biomarkers
TopicLeading institutions, researchers & key papers
This cluster of papers focuses on the advances in cancer immunotherapy research, particularly in the context of immune checkpoint blockade targeting PD-1 and PD-L1, the impact of tumor microenvironment, biomarkers for immunotherapy response, T-cell exhaustion, neoantigens, tumor mutational burden, immune-related adverse events, and the exploration of combination therapies. The research also delves into the intricate mechanisms of cancer immunoediting.
145,625
Works
2,855,057
Citations
IDs:OpenAlex
How has Cancer Immunotherapy and Biomarkers's publication output changed over time?
ScholarIQpublication output · 2010–2018
Output grew0% over the shown period — from 1 works in 2010 to 1 in 2018.
1
3
1
1
5
2
1
1
20102012201320142015201620172018
Who are the most-cited researchers behind Cancer Immunotherapy and Biomarkers?
ScholarIQtop researchers by citations
What are the most-cited papers on Cancer Immunotherapy and Biomarkers?
ScholarIQmost cited works
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Andreas D. Hartkopf, Florin‐Andrei Taran, Markus Wallwiener, Christina B. Walter, Bernhard Krämer, Eva‐Maria Grischke, Sara Y. Brucker
Breast Care. 201630,919 CitationsOPEN ACCESS
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Rimda Wanchoo, Sabine Karam, Nupur N. Uppal, Valerie S. Barta, Gilbert Deray, Craig Devoe, Vincent Launay‐Vacher, Kenar D. Jhaveri, on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors
American Journal of Nephrology. 201715,288 CitationsOPEN ACCESS
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
Nature reviews. Cancer. 201213,828 CitationsOPEN ACCESS
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure–Kunkel, Shruti Agrawal, D. G. McDonald, Georgia Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol
New England Journal of Medicine. 201212,716 CitationsOPEN ACCESS
Immunity, Inflammation, and Cancer
Sergei I. Grivennikov, Florian R. Greten, Michael Karin
Cell. 201010,771 CitationsOPEN ACCESS
Where is Cancer Immunotherapy and Biomarkers research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Cancer Immunotherapy and Biomarkers is open access?
ScholarIQopen access share
93%OPEN ACCESS
Gold
0%
Green
13%
Hybrid
0%
Bronze
80%
Closed
7%
Who collaborates most closely around Cancer Immunotherapy and Biomarkers?
ScholarIQco-authorship network
United States
75%
Netherlands
8%
France
8%
Germany
8%